Thrombopoietin receptor


  • Accession: P40238
  • Swissprot: TPOR_HUMAN
  • Organism: Homo sapiens
  • Gene: MPL
  • Target class: Membrane receptor

Drug Relations:

Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. Bioactivity details MOA
an oral, nonpeptide thrombopoietin receptor agonist Bioactivity details MOA
a thrombopoietin receptor agonist Bioactivity details MOA
Romiplostim, a member of the TPO mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor (also known as cMpl). The peptibody molecule contains two identical single-chain subunits, each consisting of human immunoglobulin IgG1 Fc domain, covalently linked at the C-terminus to a peptide containing two thrombopoietin receptor-binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. Romiplostim is produced by recombinant DNA technology in Escherichia coli. Bioactivity details MOA